Dostarlimab

多塔利单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameDostarlimab
Drug Alias NameDostarlimab-gxlyJEMPERLIJemperliWBP-285TSR-042 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursAmpullary CarcinomaMismatch Repair Deficient Cancer +[31] 
Global Approved IndicationsMismatch Repair Deficient CancerEndometrial Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/04/21
Country/TerritoryCzechiaBelgiumCanada +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAnaptysbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteSagard Healthcare Royalty Partners LPGlaxosmithkline Plc +[16] 
Inactive CompaniesWashington University School Of MedicineUniversity Of Miami
Active IndicationsSolid tumoursAmpullary CarcinomaMismatch Repair Deficient Cancer +[28] 
Inactive IndicationsMultiple MyelomaGestational Trophoblastic DiseaseSarcoma, Clear Cell

Other Information

ATC CodeL01XC40
Related LinksWikipediaDrugBankKEGG